United States · biotech/health
United States · biotech/healthRelay Therapeutics
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Public · NASDAQ:RLAYFor profit
Why reach out now
What the record says about Relay Therapeutics as a customer or partner.
- Has bought 1 companyIt has done deals before: a sign it is open to partnerships.
Against its peers
Set against 435 biotech/health companies in United States. The ring marks the typical peer.
Across all 5.9M companies: larger than 92% of those with a size listed; older than 5% of those with a founding year; website ranked #2,781,136 in the world, about 6k visits a month.
About Relay Therapeutics
BiotechnologyHealth CareTherapeutics
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$1.2B
raised in total, currency not stated across 6 rounds
Last raised Jan 2024, 2 years ago
- Rounds
- 6
- Latest round
- Post ipo equity
- Investors
- 134 leading
Corporate family
Where it sits in its group, and the deals it has done.
Key facts
Who started it and how it trades.
- Founded by
- Alexis Borisy, David E. Shaw, Dorothee Kern, Mark Murcko, Matthew Jacobson
Every detail we hold
Everything the source datasets list about Relay Therapeutics, field by field. Contact details are held but never shown.
The company7 fields
- Name
- Relay Therapeutics
- Type
- For profit
- Status
- Public · NASDAQ:RLAY
- Founded
- 2016
- Founders
- Alexis Borisy, David E. Shaw, Dorothee Kern, Mark Murcko, Matthew Jacobson
- Industry
- biotech/health
- Categories
- Biotechnology, Health Care, Therapeutics
Where3 fields
- City
- Cambridge
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach3 fields
- Staff band
- 251-500
- Web traffic rank
- #2,781,136
- Monthly web visits
- 6,168
Show 11 more fieldsShow fewer fields
Funding, as listed8 fields
- Total
- 1,200,000,000 (currency not stated)
- Rounds
- 6
- Latest round
- Post ipo equity
- Latest round date
- Jan 2024
- Investors
- 13
- Lead investors
- 4
- Stock listing
- NASDAQ:RLAY
- Listing status
- public
Corporate family1 field
- Acquisitions made
- 1
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Relay Therapeutics received a positive outlook and a reiterated buy rating from analysts. The company disclosed three new programs at a recent event. Relay Therapeutics also reported full-year 2023 earnings that exceeded expectations. However, the company ended its agreement with Genentech.
Companies like Relay Therapeutics
biotech/health in United States.
Revolution MedicinesRedwood City · 251-500 peoplefounded 1 years earlier
FreenomeSouth San Francisco · 501-1000 peoplefounded 2 years earlier
Denali TherapeuticsSan Francisco · 251-500 peoplefounded 3 years earlier
SpringWorks TherapeuticsStamford · 251-500 peoplefounded 1 years later
Arcus BiosciencesHayward · 101-250 peoplefounded 1 years earlierBuild a lead list
435 biotech/health companies in United States, filtered by size, age and reach, ready to export with emails on Pro.